期刊
JOURNAL OF VIROLOGY
卷 88, 期 12, 页码 7045-7053出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.00433-14
关键词
-
类别
资金
- National Program of Infectious Diseases [2014ZX10004001-004]
- National 973 Program [2011CB504706]
- NIH [R21AI109094, R01AI089728]
- New York Blood Center [NYB000068]
- Center of Biodefense and Emerging Infectious Disease (CBEID)
- UTMB
Prophylactic and therapeutic strategies are urgently needed to combat infections caused by the newly emerged Middle East respiratory syndrome coronavirus (MERS-CoV). Here, we have developed a neutralizing monoclonal antibody (MAb), designated Mersmab1, which potently blocks MERS-CoV entry into human cells. Biochemical assays reveal that Mersmab1 specifically binds to the receptor-binding domain (RBD) of the MERS-CoV spike protein and thereby competitively blocks the binding of the RBD to its cellular receptor, dipeptidyl peptidase 4 (DPP4). Furthermore, alanine scanning of the RBD has identified several residues at the DPP4-binding surface that serve as neutralizing epitopes for Mersmab1. These results suggest that if humanized, Mersmab1 could potentially function as a therapeutic antibody for treating and preventing MERS-CoV infections. Additionally, Mersmab1 may facilitate studies of the conformation and antigenicity of MERS-CoV RBD and thus will guide rational design of MERS-CoV subunit vaccines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据